Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
New Wins, Ongoing Challenges for ACR Insurance Subcommittee
Corrections to reimbursement system errors with Aetna and a Medicare contractor demonstrate the latest wins for all providers by the ACR’s Insurance Subcommittee. But the committee remains hard at work advocating for rheumatologists on several fronts.
Making Sense of Drug Pricing Legislation
A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.
Diet & Exercise: What’s the Economic Benefit for Overweight & Obese Patients with Knee OA?
New research recently found that, when combined with standard treatment, diet and exercise regimens are cost effective for overweight and obese patients with knee OA…
Ixekizumab vs. Adalimumab for PsA: How Do They Compare?
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…
Democrats Clash on Healthcare in Scrappy First U.S. Presidential Debate
MIAMI (Reuters)—Democratic presidential contenders battled over healthcare coverage and border policy on Wednesday during a surprisingly heated first debate that laid bare the party’s divisions on whether to abolish private insurance and shift to a Medicare-for-All system. In the first round of back-to-back debates, several of the lesser-known candidates vied for attention in the crowded…
Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…
Hot Topics, Fresh Formats: ACR/ARP Annual Meeting Clinical Session Preview
The clinical sessions at the 2019 ACR/ARP Annual Meeting feature cutting-edge techniques in rheumatology and enable attendees to hone new skills and explore medically relevant topics…
From Climbing Walls to In the Rheum: What’s New at the 2019 Annual Meeting?
This year, the Annual Meeting Planning Committee has designed an engaging program, bringing together the best experts to address important topics. Here’s a sneak peek at what’s new…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 317
- Next Page »